FIELD: biotechnology.
SUBSTANCE: invention relates to production of a new recombinant coagulation factor, which is a chimeric protein with an increased plasma half-life, consisting of human factor III and a human mutant Fc fragment of human IgG, which can be used in medicine. The resulting chimeric proteins are used as part of a pharmaceutical composition for treatment of haemostatic disorders, including for treatment of haemophilia A.
EFFECT: invention allows effective treatment of haemophilia A due to the increased half-life of the resulting coagulation factor in plasma.
15 cl, 4 dwg, 5 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED VON WILLEBRAND FACTOR WITH PROLONGED HALF-CYCLE IN VIVO, USING IT AND METHODS FOR PREPARING | 2009 |
|
RU2528855C2 |
| PREPARATIONS CONTAINING VON WILLEBRAND FACTOR (vWF) AND METHODS, KITS AND APPLICATIONS RELATED TO THEM | 2010 |
|
RU2579977C2 |
| USING OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | 2019 |
|
RU2803163C2 |
| GENETICALLY ENGINEERED POLYPEPTIDES AND USE THEREOF | 2017 |
|
RU2822498C2 |
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| HIGH GLYCATED FUSED PROTEIN BASED ON HUMAN BLOOD COAGULATION FACTOR VIII, METHOD FOR PRODUCTION THEREOF AND USE THEREOF | 2016 |
|
RU2722374C1 |
| AFFINITY CHROMATOGRAPHY WITH APPLICATION OF Fc-RECEPTORS | 2013 |
|
RU2624128C2 |
| Fc-VERSIONS WITH CHANGED BINDING WITH FcRn | 2005 |
|
RU2412200C2 |
| METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES | 2010 |
|
RU2585488C2 |
| VARIANTS OF Fc WITH CHANGED BINDING WITH FcRn | 2014 |
|
RU2700882C2 |
